Later this month at MEDICA 2009 in Düsseldorf, Germany, Zilico out of Sheffield, UK will be showing off the company’s new handheld probe for cervical cancer screening. The Zilico APX device uses electrical impedance spectroscopy to detect differences between normal, precancerous, and cancerous tissue.
Zilico is developing a new system with two applications to provide “real time” results for women undergoing both these types of test, removing several weeks of waiting for a diagnosis. The system consists of a portable hand-held device, a single use disposable sleeve and docking station. This system is safe, painless, and accurate.
Zilico was formed in 2006 as Aperio Diagnostics Ltd and has focused on developing a commercially manufactured device for the first of its applications, aimed at the colposcopy market. Clinical data on 500 women has demonstrated superior performance over existing diagnostic procedures. A multi-centre clinical trial started in April 2009.
1. Disposable sleeve – replaced for each patient
2. Wipe-clean surfaces – suitable for examination rooms
3. Wireless operation
4. On-board user interface – for ease of operation
5. Ergonomic design
6. Built-in QC tests